Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Sector Analysis

Biological Products, (No Diagnostic Substances)

Standard Industrial Classification: SIC 2836

Industry Insider Sentiment Analysis

The Biological Products, (No Diagnostic Substances) sector (SIC 2836) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.

Filing Date Trade Date Ticker Company Reporting Person Relationship Type Price Qty Total, $ Owned After
2026-11-19 21:30 2026-11-17 BSEM BioStem Technologies, Inc. Matuszewski Jason Director, Officer, 10% owner SELL $1.00 14,300 $14,300 1,539,251
2026-11-19 21:28 2026-11-17 PALI PALISADE BIO, INC. Baltera Robert Jr. Director BUY $1.01 50,000 $50,285 511,904
2026-11-19 21:08 2026-11-17 NBIX NEUROCRINE BIOSCIENCES INC LYONS GARY A Director OPT+S $164.87 15,000 $2,473,031 122,141
2026-11-19 22:58 2026-11-17 LCTX Lineage Cell Therapeutics, Inc. BROADWOOD PARTNERS, L.P. Director, 10% owner BUY $0.77 1,000,000 $770,700 50,560,992
2026-11-19 21:16 2026-11-17 LCTX Lineage Cell Therapeutics, Inc. Mulroy Michael H. Director BUY $0.87 30,000 $26,100 328,555
2026-11-19 11:32 2026-11-17 AGMB AgomAb Therapeutics NV Epstein David R Director BUY $5.57 5,000 $27,850 59,980
2026-11-18 21:30 2026-11-18 CGON CG Oncology, Inc. Kuan Arthur Director, Officer BUY $78.88 30,000 $2,366,425 228,916
2026-11-18 21:30 2026-11-18 CGON CG Oncology, Inc. Kalofonos Isabel Officer BUY $79.76 3,751 $299,161 3,751
2026-11-18 21:04 2026-11-17 ARTV Artiva Biotherapeutics, Inc. Banerjee Subhashis Officer SELL $3.91 4,037 $15,792 164,701
2026-11-18 21:04 2026-11-17 ARTV Artiva Biotherapeutics, Inc. Aslan Fred Director, Officer SELL $3.91 119,771 $468,532 1,337,657
2026-11-18 21:30 2026-11-16 WWB WINDWARD BIO GROUP AG Stampacchia Otello Director BUY $17.00 1,750,000 $29,750,000 875,000
2026-11-19 02:22 2026-11-18 AIM AIM ImmunoTech Inc. Equels Thomas K Director, Officer BUY $0.13 20,000 $2,680 386,095
2026-11-19 01:17 2026-11-17 TNYA Tenaya Therapeutics, Inc. Tingley Whittemore Officer SELL $0.32 3,223 $1,034 259,850
2026-11-19 01:18 2026-11-17 TNYA Tenaya Therapeutics, Inc. Ali Faraz Director, Officer SELL $0.32 3,499 $1,122 536,283
2026-11-19 00:30 2026-11-16 REPL Replimune Group, Inc. Hill Emily Luisa Officer SELL $21.60 14,709 $317,714 201,143
2026-11-19 00:31 2026-11-16 REPL Replimune Group, Inc. Patel Sushil Director, Officer SELL $21.60 49,026 $1,058,962 659,125
2026-11-19 00:31 2026-11-16 REPL Replimune Group, Inc. Schwendenman Andrew Officer SELL $21.60 2,148 $46,397 97,277
2026-11-19 00:32 2026-11-16 REPL Replimune Group, Inc. Xynos Konstantinos Officer SELL $21.60 16,198 $349,877 208,017
2026-11-18 23:48 2026-11-18 HALO HALOZYME THERAPEUTICS, INC. Posard Matthew L. Director SELL $96.43 5,000 $482,147 48,609
2026-11-18 23:23 2026-11-16 RVMD Revolution Medicines, Inc. Kelsey Stephen Michael Officer OPT+S $167.86 27,160 $4,559,208 286,307
2026-11-18 22:12 2026-11-16 WWB WINDWARD BIO GROUP AG Bonita David P Director, 10% owner BUY $17.00 1,176,471 $20,000,007 1,708,103
2026-11-18 22:22 2026-11-16 ATRA Atara Biotherapeutics, Inc. Nguyen AnhCo Director, Officer SELL $6.46 6,094 $39,368 126,681
2026-11-18 22:00 2026-11-17 LXEO Lexeo Therapeutics, Inc. Townsend Richard Nolan Director, Officer SELL $3.26 3,295 $10,742 373,483
2026-11-18 22:00 2026-11-17 LXEO Lexeo Therapeutics, Inc. Otero Jose Manuel Officer SELL $3.26 1,285 $4,189 137,003
2026-11-18 22:00 2026-11-17 LXEO Lexeo Therapeutics, Inc. Tamayo Louis Edward Officer SELL $3.26 1,007 $3,283 91,900
2026-11-18 22:08 2026-11-16 WWB WINDWARD BIO GROUP AG ORBIMED ADVISORS LLC Director, 10% owner BUY $17.00 1,176,471 $20,000,007 1,708,103
2026-11-18 21:36 2026-11-16 MRNA Moderna, Inc. Hoge Stephen Officer OPT+S $215.63 78,375 $16,900,017 1,311,095
2026-11-18 21:05 2026-11-16 TWST Twist Bioscience Corp Laponis Adam Officer SELL $103.69 6,359 $659,352 118,501
2026-11-18 21:05 2026-11-16 TWST Twist Bioscience Corp WERNER ROBERT F. Officer SELL $103.69 1,637 $169,737 49,571
2026-11-18 21:05 2026-11-16 TWST Twist Bioscience Corp Leproust Emily M. Director, Officer SELL $103.69 19,045 $1,974,738 634,493
2026-11-18 21:05 2026-11-16 TWST Twist Bioscience Corp Green Paula Officer SELL $103.69 4,281 $443,888 121,773
2026-11-18 21:05 2026-11-16 TWST Twist Bioscience Corp Finn Patrick John Officer SELL $103.69 12,752 $1,322,229 221,161
2026-11-18 21:05 2026-11-16 TWST Twist Bioscience Corp Cho Dennis Officer SELL $103.69 5,427 $562,715 80,238
2026-11-18 21:05 2026-11-17 ARTV Artiva Biotherapeutics, Inc. Bush Jennifer Officer SELL $3.91 19,217 $75,175 338,503
2026-11-18 21:05 2026-11-17 ARTV Artiva Biotherapeutics, Inc. Horan Christopher Officer SELL $3.91 20,546 $80,374 281,775
2026-11-18 21:06 2026-11-17 ARTV Artiva Biotherapeutics, Inc. Miralles Gines Diego Officer SELL $3.91 1,043 $4,080 121,457
2026-11-18 13:33 2026-11-17 CMPX Compass Therapeutics, Inc. Lerner Neil Officer BUY $0.59 10,000 $5,900 430,000
2026-11-17 21:30 2026-11-16 CGON CG Oncology, Inc. POST LEONARD E Director OPT+S $92.00 1,000 $92,000 1,000
2026-11-18 02:01 2026-11-17 MGTX MeiraGTx Holdings plc Forbes Alexandria Director, Officer SELL $8.45 62,000 $523,900 1,239,595
2026-11-18 01:29 2026-11-16 GILD GILEAD SCIENCES, INC. Dickinson Andrew D Officer SELL $171.47 3,000 $514,410 158,096
2026-11-18 01:32 2026-11-16 GILD GILEAD SCIENCES, INC. Mercier Johanna Officer OPT+S $170.55 28,000 $4,775,529 110,684
2026-11-18 00:00 2026-11-13 TARS Tarsus Pharmaceuticals, Inc. Azamian Bobak R. Director, Officer SELL $80.31 10,000 $803,100 817,991
2026-11-17 23:08 2026-11-16 LCTX Lineage Cell Therapeutics, Inc. ANDREWS DEBORAH J Director BUY $0.80 25,000 $20,000 40,578
2026-11-17 21:05 2026-11-13 VCEL Vericel Corp SIEGAL JONATHAN Officer OPT+S $57.71 1,885 $108,779 1,259
2026-11-17 15:00 2026-11-16 AIM AIM ImmunoTech Inc. Equels Thomas K Director, Officer BUY $0.14 38,000 $5,130 366,095
2026-11-17 13:45 2026-11-16 LCTX Lineage Cell Therapeutics, Inc. Culley Brian M Director, Officer BUY $0.92 40,500 $37,098 296,016
2026-11-16 22:00 2026-11-16 LCTX Lineage Cell Therapeutics, Inc. Howe Jill Ann Officer BUY $0.86 20,000 $17,100 45,500
2026-11-16 22:22 2026-11-16 AURA Aura Biosciences, Inc. Hopkins Janet Jill Officer SELL $7.05 16,903 $119,166 363,287
2026-11-17 02:01 2026-11-16 ADMA ADMA BIOLOGICS, INC. Grossman Adam S Director, Officer OPT+S $13.72 21,000 $288,120 2,064,777
2026-11-17 02:05 2026-11-16 ADMA ADMA BIOLOGICS, INC. Guiheen Lawrence P. Director OPT+S $13.92 10,000 $139,200 63,599
SHOW ENTRIES

Sector-Wide Insider Alpha

Analyzing insider movements across the Biological Products, (No Diagnostic Substances) sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2836) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.

SEC Filings in Biological Products, (No Diagnostic Substances)

Every transaction in the Biological Products, (No Diagnostic Substances) industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.